You are here: Industry Insights > novo

News List

Esco Lifesciences Closes a Record-Setting US$200M Series A Round Led by Vivo Capital and Novo Holdings prnasia
May 27, 2021
Esco Lifesciences announced today the close of an over-subscribed US$200 million Series A and Crossover round. The financing was led by Vivo Capital and Novo Holdings A/S, with participation from new investors including China Investment Corporation ...
Numab Therapeutics secures $110m in Series C funding round pharmaceutical-technology
May 24, 2021
Numab Therapeutics has raised approximately $110m (CHF100m) through Series C funding to expedite the clinical development of its multi-specific antibody pipeline in oncology and inflammation.
Novo Nordisk's Tresiba misses main mark in head-to-head tilt with Sanofi's Toujeo fiercepharma
September 26, 2019
Novo also pointed to Tresiba’s ability to reduce the rate of severe hypoglycemia by 80% against Toujeo and pare down the rate of nocturnal hypoglycemia by 37% during that same 36-week period.
Novo prices oral Rybelsus on par with injectable rivals, ending discount fears fiercepharma
September 26, 2019
Novo will be working to secure payer coverage as quickly as possible as part of the “strike model” it intends to use for Rybelsus’ rollout in the U.S. As it did with Ozempic, the company will start out targeting specialists, only moving to primary care ph
FDA approves oral semaglutide Rybelsus to treat type 2 diabetes pharmaceutical-technology
September 26, 2019
FDA approval comes from results from ten PIONEER clinical trials conducted in a total of 9,543 adult type 2 diabetes patients.
Novo Nordisk to provide discounted insulin products in US pharmaceutical-technology
September 10, 2019
Dutch pharmaceutical company Novo Nordisk has announced plans to sell authorised generics of its insulin drug Novolog at a reduced price in the US.
Novo Nordisk files lawsuit against Mylan for generic application europeanpharmaceuticalreview
August 27, 2019
The two pharmaceutical companies are facing a legal battle after Mylan filed a new drug application for a generic of Novo Nordisk’s Victoza.
Investors angry about insulin woes sue Novo Nordisk in Denmark for $1.75B fiercepharma
August 18, 2019
Novo’s been relying less on insulins for growth these days as its GLP-1 franchise steams ahead. But trouble in its insulin franchise still lingers—and now it'll have to defend against a group of investors who sued in Denmark, claiming it made “misleading”
Positive results for Novo’s Xultophy pharmatimes
June 11, 2019
“In clinical practice this becomes relevant as the longer a patient can remain in good control, the less exposure there is to high blood sugar, and the fewer escalations, or changes, in therapy are required.”
Diabetes coverage is improving, but could a shake-up be on the way with Novo’s oral semaglutide? fiercepharma
March 06, 2019
Payer pressure has been squeezing diabetes drugs, leading to some major sales difficulties and layoff rounds. As Bernstein analyst Wimal Kapadia observes, things are on the mend in terms of 2019 formulary coverage, but one drug could “disrupt them all.”

Previous page 1 2 3 4 Next page